Venter W.D.F.

Publications

512

Citations

18.9K

h-index

66

Publishing journals

153

Years of publications

20+

Active since

2007

References

17.3K

1. A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens.
   The Journal of antimicrobial chemotherapy, Volume 81, Issue 1, No. dkaf445, Year 2026
2. GLP-1 Receptor Agonists and the Path to Sustainable Obesity Care
   JAMA Internal Medicine, Volume 184, Issue 12, Pages 8-8, Year 2025
3. Causes of death in adults living with HIV in South Africa: A single-centre postmortem study.
   Southern African journal of HIV medicine, Volume 26, Issue 1, No. a1673, Pages 1673-1673, Year 2025
4. Reaching priority populations with different HIV self-testing distribution models in South Africa: an analysis of programme data
   BMC Infectious Diseases, Volume 22, Issue S1, Pages 981-981, Year 2025
5. Working at Cross-PURPOSEs to Ending HIV
   The New England journal of medicine, Volume 392, Issue 13, Pages 1344-1345, Year 2025
6. The impact of United States Government cuts to funding on South African Healthcare and Research
   Wits Journal of Clinical Medicine, Volume 7, Issue 2, Year 2025
7. The Need for Lenacapavir Compulsory Licences in Ending the HIV Epidemic
   Clinical Infectious Diseases, Volume 81, Issue 3, Pages 547-554, Year 2025
8. Prolonged Diagnostic Interval Leads to High Lymphoma Related Mortality in a Prospective Cohort of People with HIV Undergoing Fine Needle Aspiration
   Cancers, Volume 17, Issue 6, No. 1005, Page 1005, Year 2025
9. The association of HIV status and depressive symptoms in the Ndlovu Cohort study
   Scientific Reports, Volume 15, Issue 1, No. 4539, Pages 4539-4539, Year 2025
10. Pulmonary manifestations of long COVID in Johannesburg, South Africa
    Southern African Journal of Infectious Diseases, Volume 40, Issue 1, No. a734, Pages 734-734, Year 2025
11. The Association Between HIV-Related Stigma, ART Adherence, and Cardiovascular Disease Risk in People Living With HIV
    Journal of Acquired Immune Deficiency Syndromes (1999), Volume 99, Issue 2, Pages 107-115, Year 2025
12. Exploring barriers to hypertension medication adherence among people living with HIV enrolled in the iHEART-SA trial: a theoretical domains framework qualitative study
    BMC Public Health, Volume 26, Issue 1, Pages 125-125, Year 2025
13. Leveraging community pharmacies for HIV services in South Africa: Opportunities and constraints.
    Southern African journal of HIV medicine, Volume 26, Issue 1, No. a1739, Page 1739, Year 2025
14. Pharmacokinetics, pharmacogenetics, and toxicity of co-administered efavirenz and isoniazid.
    Southern African journal of HIV medicine, Volume 26, Issue 1, No. a1661, Page 1661, Year 2025
15. Concurrent Tuberculosis and COVID-19 Testing from a Single Sputum Specimen for Enhanced Disease Detection
    Diagnostics, Volume 15, Issue 6, No. 720, Page 720, Year 2025
16. Perceptions of Health, Body Size, and Nutritional Risk Factors for Obesity in People with HIV in South Africa
    UNC Libraries, Year 2025
17. The Effect of Rifampicin on the Plasma and Intracellular Pharmacokinetics of Tenofovir Alafenamide Fumarate in Participants with HIV-associated Tuberculosis.
    Journal of acquired immune deficiency syndromes (1999), Year 2025
18. Initiation of Dolutegravir Versus Efavirenz on Viral Suppression and Retention at 6 months: A Regression Discontinuity Design
    Journal of Acquired Immune Deficiency Syndromes (1999), Volume 99, Issue 2, Pages 151-157, Year 2025
19. Long-acting antiretroviral therapy in low-income and middle-income countries: considerations for roll-out
    Current Opinion in HIV and AIDS, Volume 20, Issue 1, Pages 19-24, Year 2025
20. Initiation of dolutegravir vs. efavirenz on 12- and 24-month retention and viral suppression: a target trial emulation
    Infectious diseases (London, England), Volume 58, Issue 2, Pages 198-208, Year 2025

No publications in the index yet.